echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Clinical approval document of mansuoshuli tablet

    Clinical approval document of mansuoshuli tablet

    • Last Update: 2017-12-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: Sina medical news 2017-12-06 On the evening of December 4, humanwell Pharmaceutical Group Co., Ltd (hereinafter referred to as "the company" or "humanwell pharmaceutical") announced that recently, Wuhan Guanggu humanwell biomedical Co., Ltd (hereinafter referred to as "Guanggu humanwell", the company holds 32.52% of its equity, the first major shareholder) received the approval and issuance of "meisuoshuli tablet" from the State Food and drug administration ”Approval for clinical trials of drugs Meisuoshuli is a new chemical drug of category 1.1 Guanggu humanwell has obtained three Chinese patent authorizations (zl200380108063.9, zl201310476323.3, zl201410438726.3) At present, there are no other manufacturers at home and abroad listing or R & D application information Meisuoshuli has anti-inflammatory, analgesic and antipyretic effects It can be used for pain and inflammation after operation and acute trauma, pain and dysmenorrhea caused by inflammation of otorhinopharynx, fever caused by upper respiratory tract infection and chronic arthritis (such as rheumatoid arthritis and osteoarthritis) Nimesulide is a non steroidal anti-inflammatory drug with anti-inflammatory, analgesic and antipyretic effects According to the data of minenet, at present, the main domestic manufacturers include Lepu Pharmaceutical (Beijing) Co., Ltd and Kangzhi Pharmaceutical Co., Ltd, In 2016, the amount of drugs used in domestic sample hospitals of all formulations of nimesulide was about 200 million yuan In January 2013, Guanggu humanwell submitted the application for clinical registration of meisuoshuli and was accepted In June 2014, it obtained the approval document for phase I clinical trial After the completion of phase I clinical trial, it applied for phase II / III clinical trial The announcement also revealed that up to now, about 15 million yuan has been invested After receiving the approval documents for clinical trials of the above drugs, the company will continue to carry out clinical studies of the drugs
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.